CATAPRES-TTS-1 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Catapres-tts-1, and what generic alternatives are available?
Catapres-tts-1 is a drug marketed by Lavipharm and is included in one NDA.
The generic ingredient in CATAPRES-TTS-1 is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Catapres-tts-1
A generic version of CATAPRES-TTS-1 was approved as clonidine by DIFGEN PHARMS on August 18th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CATAPRES-TTS-1?
- What are the global sales for CATAPRES-TTS-1?
- What is Average Wholesale Price for CATAPRES-TTS-1?
Summary for CATAPRES-TTS-1
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 71 |
| Clinical Trials: | 19 |
| Patent Applications: | 5,389 |
| What excipients (inactive ingredients) are in CATAPRES-TTS-1? | CATAPRES-TTS-1 excipients list |
| DailyMed Link: | CATAPRES-TTS-1 at DailyMed |
Recent Clinical Trials for CATAPRES-TTS-1
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rigshospitalet, Denmark | Phase 2/Phase 3 |
| Deventer Ziekenhuis | Phase 3 |
| King's College London | Phase 3 |
Pharmacology for CATAPRES-TTS-1
| Drug Class | Central alpha-2 Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha2-Agonists |
US Patents and Regulatory Information for CATAPRES-TTS-1
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CATAPRES-TTS-1
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CATAPRES-TTS-1
See the table below for patents covering CATAPRES-TTS-1 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 1445538 | ⤷ Sign Up | |
| Portugal | 67128 | SYSTEME TERAPEUTIQUE POUR ADMINISTRE CLONIDYNE AU TRAVERS DE LA DERME ET PROCEDE POUR SA PREPARATION | ⤷ Sign Up |
| Czechoslovakia | 216917 | METHOD OF MAKING THE THERAPEUTIC SYSTEM FOR THE TRANSDERMAL SERVING OF THE CLONIDINE | ⤷ Sign Up |
| Switzerland | 646876 | ARZNEIMITTEL ENTHALTENDES HAUTPFLASTER UND VERFAHREN ZU DESSEN HERSTELLUNG. | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
